UK breast cancer trial tests five-day radiotherapy
When we talk about cancer care, the science matters. So does the calendar. The Department of Health and Social Care says more than 1,000 people have now joined a UK trial testing whether breast cancer radiotherapy can be shortened from three weeks to just five days. That sounds technical, but the everyday meaning is simple. If the treatment proves safe and effective, some patients could avoid around 10 trips to hospital. For people trying to balance work, childcare, travel costs and recovery, that is not a small change. It is time, energy and stress that might be given back.
The study is called the FAST-Forward Boost trial. In plain English, researchers are testing a shorter course of radiotherapy with an extra targeted dose, known as a boost, to help stop the cancer returning in the breast. The trial is running at 39 hospitals across the UK, so this is not a small single-site experiment. According to the government announcement, the trial is led by The Institute of Cancer Research, London, funded by the National Institute for Health and Care Research, and delivered with NHS teams including The Royal Marsden NHS Foundation Trust. Hospitals taking part stretch from London, Cambridge and Manchester to Swansea, Edinburgh and Belfast. Chief investigator Professor Anna Kirby says reaching 1,000 participants reflects the commitment of patients and clinical teams across the country.
It is also worth slowing down here and being precise. A trial is not the same thing as a new national standard. Researchers still need to recruit 4,830 people by 2028, follow participants for five years and study the results properly, with findings expected in 2033. That caution matters because shorter treatment only helps if it is just as safe and just as good at controlling the disease. If it works, the gain could be wide: less disruption for patients and families, lower travel costs, and more NHS capacity for other people waiting for treatment. But the evidence has to come first.
The government is pairing that research message with a public one about screening. As the latest figures were published, Health and Social Care Secretary Yvette Cooper urged women to take up the offer of breast screening. NHS screening figures for England show that 63.6% of women invited for their first appointment attended, the highest first-invite rate in the past decade. Even so, around four in 10 first-time invitees still did not go. If you get a letter and feel completely well, it can be tempting to put it to one side. Screening is different from going to the doctor with a symptom. It is there to spot possible signs of cancer earlier, before they become harder to treat. Breast Cancer Now says around 30% of female breast cancers in England are diagnosed through screening, and most of those are found at an early stage.
Earlier diagnosis is not just a slogan. Breast Cancer Now says that when breast cancer is diagnosed at stage 1, almost 100% of people survive for five years or more. At stage 4, that figure falls to 32%. Those numbers help explain why early detection keeps coming up in government plans and charity campaigns. But we should be careful not to turn that into blame. People miss appointments for all sorts of reasons, including fear, caring duties, work, transport and past bad experiences of healthcare. If ministers want higher uptake, the task is not only to tell women to come forward. It is to make screening easier to reach, easier to trust and easier to understand.
Patient voice is also being given a more formal place in the National Cancer Plan. Ashley Dalton MP, who is living with metastatic breast cancer, has been appointed to advise on how the plan is delivered. Metastatic, also called secondary, breast cancer means the disease has spread beyond the breast. The government says Dalton stepped down as Parliamentary Under-Secretary of State for Public Health and Prevention on 2 March 2026 to manage her health and treatment side effects. That appointment matters beyond Westminster. When policy is shaped only by targets and press releases, everyday reality can slip out of view. Dalton brings both ministerial experience and lived experience, and she has said she wants to help push the plan towards its 2035 aim: that three in four people diagnosed with cancer will be cancer free or living well with cancer five years after diagnosis.
The wider package goes beyond one trial. The Department of Health and Social Care says ministers, NIHR and NHS England are also backing studies that use AI to support the reading of mammograms, while a three-year partnership with Breast Cancer Now is meant to help women recognise symptoms and find trusted information and support after treatment. In this case, AI means software being tested to assist specialists, not replace them. Put together, this is really a story about time. Time saved in hospital if radiotherapy can be shortened. Time gained when cancer is found earlier. Time protected when good support helps people live better during and after treatment. The hard part now is delivery: finishing the trial, widening access to screening and making sure patient experience is treated as evidence, not an afterthought.